A look back at the medical miracles of 2025

Dr. Marc Siegel reviewed notable 2025 medical advances on Fox & Friends, highlighting innovations that include a pineapple-derived topical burn cream and a newly approved heart procedure. Although the segment did not cite specific companies, revenues or trial data, these kinds of approvals and novel biologically derived products can create commercial upside for healthcare and medtech firms — contingent on regulatory, reimbursement and clinical adoption developments that will drive investor interest and potential valuation/ licensing activity.

Analysis

Market structure: The obvious winners are specialized structural‑heart device makers (Edwards Lifesciences EW, Boston Scientific BSX, Abbott ABT) and faster‑to‑market consumer/OTC brands (Kenvue KENV, JNJ consumer) that can commercialize a pineapple‑derived burn cream; losers are undifferentiated OTC/generic topical makers and small-cap wound‑care OEMs facing margin compression. Pricing power should skew toward patented devices and branded topicals (premium pricing +10–30% vs commoditized peers) while commodity pressure on bromelain (pineapple enzyme) could bid raw‑material costs modestly higher if scaled quickly.

Risk assessment: Tail risks include FDA post‑market safety actions, CMS non‑coverage or restrictive coding (low‑probability, high‑impact), or a supply shock to bromelain (could spike input costs 30–100% if single‑source). Immediate (days) reaction is hype and small‑cap volatility, short‑term (3–9 months) hinges on payer/CMS decisions and manufacturing scale, long‑term (1–3 years) on real adoption curves and clinical outcomes; watch IP/licensing clauses and offshore supply chains as hidden dependencies.

Trade implications: Direct plays favor initiating 2–3% positions in EW and 1–2% in BSX/ABT over 2–6 weeks, with 6–9 month call spreads (buy 20–30% OTM, sell 50% OTM) sized 0.5–1% notional to capture adoption while limiting spend. Rotate 2–4% from mega‑cap tech into medtech/consumer healthcare; hedge regulatory/downside risk with 3–6 month puts on the biotech ETF IBB sized 0.5–1% notional. Entry: act on post‑approval commercial partnerships or first CMS guidance (expected 30–90 days); exit or trim if first‑year uptake <30% of modeled eligible patients.

Contrarian angles: Consensus likely overstates near‑term revenue — remember TAVR adoption took 3–5 years to materially expand revenues; early small‑cap winners may be overbought and vulnerable to reimbursement lag. Mispricings exist in specialist device makers that trade below peers due to headline indifference; unintended consequences include rapid raw‑material rallies or IP litigation that could cut margins by >5–10% for OTC entrants within 12 months.

Key Decisions for Investors

• Establish a 2–3% long position in Edwards Lifesciences (EW) within 2–4 weeks, scaling in on any pullbacks of 5–10%; target a 12‑month upside of ~20% and trim if 12‑month adoption metrics show <30% penetration of the eligible cohort.
• Buy a 6–9 month call spread on Boston Scientific (BSX) sized 0.5–1% notional: buy calls ~20–30% OTM and sell calls ~50% OTM to capture upside from structural‑heart procedure adoption while limiting premium outlay; close or roll if CMS issues restrictive coverage within 90 days.
• Initiate a 1–2% position in Kenvue (KENV) or JNJ consumer segment for topical burn cream upside; increase to 3–4% only if first‑quarter global sales exceed $50M and gross margins remain >40% reported in the following 90 days.
• Hedge sector/regulatory tail risk by buying 3–6 month puts on IBB (size 0.5–1% notional). If no adverse FDA/CMS notices arrive within 90 days, reduce hedge exposure by 50%; if a major post‑market safety or non‑coverage announcement occurs, increase hedge to 2% notional.